PDCD1 and non-small cell lung carcinoma: The overall adverse reactions of apatinib plus PD-1 inhibitors were acceptable and manageable, which was in line with the safety profile of the previous study regarding the combination therapy of apatinib plus PD-1 inhibitors among patients with advanced NSCLC [30].